Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 16, 2002

View Archived Issues

Dual inhibitor of ECE-1 and NEP demonstrates efficacy in preclinical studies

Partaject-delivered busulfan granted orphan drug status

Quick-Med licenses technologies from U. of Florida

The antisense oligonucleotide oblimersen sodium a highlight of the ASH meeting

Novel agents for ischemic conditions identified by Galileo researchers

GSK presents several series of urotensin-II antagonists

Fujisawa and Daiso present novel compounds with apo B secretion-inhibitory activity

VEGFR inhibitors and their use in psoriasis and other disorders

Bayer presents new thyroid hormone-like compounds for use in arteriosclerosis therapy

Safety restrictions announced for Eprex/Erypo in patients with chronic renal failure

GenVec and Fuso collaborate to develop targeted cancer therapy candidate

Athersys and U. of Minnesota to develop adult stem cell technology

Cell Genesys and VectorLogics collaborate on second-generation oncolytic virus therapies

Corus-1020 completes phase I study

VEGF gene transfer evaluated for diabetic neuropathy in NIH-funded trial

U. of Arkansas to assess CEL-1000 against Chlamydia

Efficacy of bortezomib in hematological malignancies

Tempostatin enters phase II trial for recurring bladder cancer

IDEC-114 reported safe and effective in refractory follicular lymphoma

New data on bryostatin 1 combined with fludarabine in CLL

No objective antitumor responses in AML patients treated with PTK-787/ZK-222584

Disappointing phase III preliminary results for CeaVac in colorectal cancer

AP-158 kills mupirocin-resistant bacteria in vivo

Merck & Co. plans growth in 2003 on two fronts

Oxime tachykinin antagonist with oral activity and potential as an asthma therapy

Merck KGaA announces name changes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 27, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...